About VycellixTM, Inc.
Founded by leading medical researchers at the Karolinska Institute in Sweden, Vycellix’s mission is to deliver best-in-class allogeneic cell-based therapies while eliminating the likelihood of immune rejection. The Company has developed a broad suite of cell therapy engineering solutions including its lead asset, VY-UC, which is the only single-step, universal cell strategy shown to prevent the formation of immune synapse to generate immune privileged cells, thus redefining the paradigm for donor-based medicines.
Leveraging the benefits of its VY-UC platform, Vycellix is preparing to initiate human clinical evaluations for VY-UC-NK, an off-the-shelf natural killer cell (NK cell) product candidate being advanced for the treatment of hematological malignancies.
Beyond VY-UC, Vycellix’s cell engineering tools pipeline represents ideal solutions with market leading potential to enhance gene delivery, accelerate cell expansion, increase cell potency, and optimize multi-antigen engagement.
Karolinska Institutet & NextGenNK:
Vycellix’s platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. The Company is also a collaborative partner in NextGenNK. Based at KI, NextGenNK is the Swedish Innovation Agency’s Competence Center for the development of next-generation NK cell-based cancer immunotherapies. KI is recognized for its Nobel Assembly, which annually awards the Nobel Prize in Physiology or Medicine.
Vycellix Sweden AB:
Vycellix Sweden AB is a wholly-owned subsidiary of Vycellix, Inc. and is located on Karolinska Institutet’s Flemingsberg campus at Innovation Station. Vycellix Sweden is engaged in discovery-stage cancer immunotherapy research, which is conducted in collaboration with leading researchers at KI.
To learn more about Vycellix Sweden, please visit: https://vycellixsweden.com/